翰思艾泰生物医药科技（武汉）股份有限公司（翰思艾泰-B，股票代码：03378）于2026年5月29日发布翌日披露报表，宣布于香港联交所场内回购18,200股H股普通股，占该次回购前已发行股本约0.013%。本次回购价格区间为每股25.60港元至28.58港元，成交量加权平均价约26.24港元，合计涉资约47.75万港元。
回购完成后，公司已发行股份数由135,371,030股降至135,352,830股，库藏股数由847,800股增至866,000股。根据公司资料，此次股份回购授权的决议通过于2026年2月12日，公司可回购的股份总数为13,621,883股，截至目前已在交易所累计购回866,000股，占授权通过日已发行股本约0.6357%。公司并确认，此次回购已遵守香港联交所上市规则及相关法规，后续新股发行或再出售库藏股将暂缓至2026年6月28日。
本公告由董事长兼执行董事张发明签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.